Visus enters licensing agreements with Cella, DelSiTech
Click Here to Manage Email Alerts
Visus Therapeutics has entered into worldwide exclusive licensing agreements with Cella Therapeutics and DelSiTech, according to a press release.
The agreement with Cella involves developing treatments for glaucoma and age-related macular degeneration, while the agreement with DelSiTech involves developing treatments “using a biodegradable, silica-based, sustained-release technology” to overcome limitations of ophthalmic therapies, the release said
“By expanding our portfolio to include investigational drugs for glaucoma and age-related macular degeneration and leveraging this innovative drug delivery technology, Visus Therapeutics is well positioned to develop a new generation of therapies that could potentially change the standard of care for these sight-threatening conditions,” Ben Bergo, co-founder and CEO at Visus Therapeutics, said in the release.
Through the Cella agreement, Visus “will advance preclinical programs targeting elevated intraocular pressure, neuroprotection and neuroenhancement in patients with glaucoma and geographic atrophy secondary to AMD,” the release said.
Terms of the agreements were not released.
Read more about
Click Here to Manage Email Alerts